These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 16838426)

  • 1. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Olofsson B; Puu M; Yusuf S;
    Am Heart J; 2006 Jul; 152(1):86-92. PubMed ID: 16838426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
    Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Yusuf S
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
    J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Solomon SD; Wang D; Finn P; Skali H; Zornoff L; McMurray JJ; Swedberg K; Yusuf S; Granger CB; Michelson EL; Pocock S; Pfeffer MA
    Circulation; 2004 Oct; 110(15):2180-3. PubMed ID: 15466644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
    Demers C; McMurray JJ; Swedberg K; Pfeffer MA; Granger CB; Olofsson B; McKelvie RS; Ostergren J; Michelson EL; Johansson PA; Wang D; Yusuf S;
    JAMA; 2005 Oct; 294(14):1794-8. PubMed ID: 16219883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.
    Castagno D; Skali H; Takeuchi M; Swedberg K; Yusuf S; Granger CB; Michelson EL; Pfeffer MA; McMurray JJ; Solomon SD;
    J Am Coll Cardiol; 2012 May; 59(20):1785-95. PubMed ID: 22575317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin inhibition in heart failure.
    McMurray JJ
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S17-22. PubMed ID: 15526237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study of the month. The CHARM study].
    Kulbertus H
    Rev Med Liege; 2003 Oct; 58(10):646-52. PubMed ID: 14677527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
    Cohen-Solal A; McMurray JJ; Swedberg K; Pfeffer MA; Puu M; Solomon SD; Michelson EL; Yusuf S; Granger CB;
    Eur Heart J; 2008 Dec; 29(24):3022-8. PubMed ID: 18987098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
    Granger CB; McMurray JJ; Yusuf S; Held P; Michelson EL; Olofsson B; Ostergren J; Pfeffer MA; Swedberg K;
    Lancet; 2003 Sep; 362(9386):772-6. PubMed ID: 13678870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
    O'Meara E; Lewis E; Granger C; Dunlap ME; McKelvie RS; Probstfield JL; Young JB; Michelson EL; Ostergren J; Carlsson J; Olofsson B; McMurray J; Yusuf S; Swedberg K; Pfeffer MA
    Eur J Heart Fail; 2005 Jun; 7(4):650-6. PubMed ID: 15921807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
    Desai AS; Swedberg K; McMurray JJ; Granger CB; Yusuf S; Young JB; Dunlap ME; Solomon SD; Hainer JW; Olofsson B; Michelson EL; Pfeffer MA;
    J Am Coll Cardiol; 2007 Nov; 50(20):1959-66. PubMed ID: 17996561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
    McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
    Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving outcomes in chronic heart failure.
    Komajda M
    Drugs Today (Barc); 2006 Dec; 42 Suppl C():29-36. PubMed ID: 17245479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.
    Swedberg K; Pfeffer M; Granger C; Held P; McMurray J; Ohlin G; Olofsson B; Ostergren J; Yusuf S
    J Card Fail; 1999 Sep; 5(3):276-82. PubMed ID: 10496201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
    Hillege HL; Nitsch D; Pfeffer MA; Swedberg K; McMurray JJ; Yusuf S; Granger CB; Michelson EL; Ostergren J; Cornel JH; de Zeeuw D; Pocock S; van Veldhuisen DJ;
    Circulation; 2006 Feb; 113(5):671-8. PubMed ID: 16461840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Pocock S; Wang D; Wilhelmsen L; Hennekens CH
    Am Heart J; 2005 May; 149(5):939-43. PubMed ID: 15894981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.